Gilead is going to Shanghai for its latest expansion in the hot inflammation market, dishing out $1.28 billion upfront to PepStar Therapeutics for a Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.